Back to today’s briefing

Story perspectives

Eli Lilly's Earnings Surge, Stock Plummets Despite Optimism

8/7/2025

24 5

Summary

Story summary

Eli Lilly's Q2 2025 earnings soared by 38% to $15.56 billion, fueled by robust sales of Mounjaro and Zepbound. However, the stock plummeted 14.53% after lackluster results from the orforglipron weight-loss trial. Despite this setback, analysts are hopeful, forecasting a remarkable 29.8% upside for the stock's future.

History

Historical Context

Eli Lilly and Company, founded in 1876, became a leader in pharmaceuticals, introducing significant products like insulin and Prozac, approved by the FDA in 1987. The approval of Prozac marked a turning point for the company, contributing to its growth. As of 2025, Eli Lilly's innovations in weight-loss medications, including Mounjaro and Zepbound, reflect ongoing industry volatility and potential for expansion.

1 of 2

Story summary

Eli Lilly's Q2 2025 earnings soared by 38% to $15.56 billion, fueled by robust sales of Mounjaro and Zepbound. However, the stock plummeted 14.53% after lackluster results from the orforglipron weight-loss trial. Despite this setback, analysts are hopeful, forecasting a remarkable 29.8% upside for the stock's future.

1 / 2